Like Us
Plus One
Follow Us
Search
 Author Office Team  Views 433 View Original Article

Today’s post was written by Ron Markezich, corporate vice president for Microsoft. With 22 acquisitions in the past five years, it’s easy to see how Allergan is a leading exponent of the new “Growth Pharma” business model. Expanding its diversified portfolio of branded and generic pharmaceuticals by acquiring companies like Botox and Zeltiq Aesthetics, Allergan is pursuing a rigorous growth strategy, rather than investing heavily in R&D. This approach, known in the industry as “open scien…
View Original Article

Recent Articles from Office Blogs